royal dsm capital markets day 2015 amsterdam

162 Pages·2015·5.86 MB·English

COVER SHEET
ROYAL DSM
CAPITAL MARKETS DAY 2015
AMSTERDAM
©2015 KENTIEDESIGN BNO
BOILERPLATE — INSIDE COVER
DSM – Bright Science. Brighter Living.™
Royal DSM is a global science-based company active in health, nutrition and materials. DSM is driving economic prosperity, environmental
progress and social advances to create sustainable value for all stakeholders simultaneously. DSM delivers innovative solutions that
nourish, protect and improve performance in global markets such as food and dietary supplements, personal care, feed, medical devices,
automotive, paints, electrical and electronics, life protection, alternative energy and bio-based materials. DSM and its associated
companies deliver annual net sales of about €10 billion with approximately 25,000 employees. The company is listed on Euronext
Amsterdam. More information can be found at www.dsm.com.
ROYAL DSM CAPITAL MARKETS DAY
4 NOVEMBER 2015 AMSTERDAM
©2015 KENTIEDESIGN BNO
CONTENT SHEET
Content
STRATEGY 2018
1 Feike Sijbesma, CEO / Chairman of the Managing Board
Driving Profitable Growth
STRATEGY 2018
2 Dimitri de Vreeze, Performance Materials / Member of the Managing Board
Driving Profitable Growth in Performance Materials
STRATEGY 2018
3 Stephan Tanda, Nutrition / Member of the Managing Board
Driving Profitable Growth in Nutrition
STRATEGY 2018
4 Geraldine Matchett, CFO / Member of the Managing Board
Driving Profitable Growth
ROYAL DSM CAPITAL MARKETS DAY
4 NOVEMBER 2015 AMSTERDAM
©2015 KENTIEDESIGN BNO
TAB 1
STRATEGY 2018
Driving Profitable Growth
FEIKE SIJBESMA
CEO / Chairman of the Managing Board
1
©2015 KENTIEDESIGN BNO
DSM STRATEGY 2018
Driving Profitable Growth
through science-based, sustainable solutions
FeFiEkIeK SEi jSbIeJBsmESaM - AC E- OC EO
[D raft Version 29 (15.00 hour) - 10 -2015 ]
Version 0; 21 September 2015

Presentation Geraldine Matchett, CFO
[classification: secret]
4 November 2015
ROYAL DSM CAPITAL MARKETS DAY
4 NOVEMBER 2015 AMSTERDAM
Safe harbor statement

This presentation may contain forward-looking statements with respect to DSM’s future (financial) performance
and position. Such statements are based on current expectations, estimates and projections of DSM and
information currently available to the company. DSM cautions readers that such statements involve certain risks
and uncertainties that are difficult to predict and therefore it should be understood that many factors can cause
actual performance and position to differ materially from these statements. DSM has no obligation to update the
statements contained in this presentation, unless required by law.

A more comprehensive discussion of the risk factors affecting DSM’s business can be found in the company’s latest
Annual Report, which can be found on the company's corporate website, www.dsm.com

Slide 1
Agenda

1 Strategy 2010-15
− Successful transformation
− Good growth platform created
•2 Strategy 2018
− Improve financial results, through
• Organic growth & business strategies
• Cost reduction & productivity improvements
• Capital efficiency
• Organization and culture
− Build for further future growth
− Extract value from Pharma & Bulk Chemicals
−3 Wrap-up
Slide 2
Strategy 2010-15: Successful transformation

 Finalized important transformation steps
− 2010-11 Base Chemicals divestments
− Partnerships for Pharma in 2012 (Antibiotics) and 2014 (Contract Manufacturing)
− Partnership for Bulk Chemicals in 2015
 Created a high-value portfolio
− Built a broad, deep and global Nutrition business
− Upgraded Performance Materials businesses
− Became a more global, innovative and sustainable company
− Created 3 new growth platforms

Slide 3
Business portfolio streamlined and simplified,
creating good platform for growth
Sales split – 2010 vs. 15 (€m) EBITDA split – 2010 vs. 15 (€m)1
9,000 2 1,400
8,176 2 1,161
6% 5% Sizeable Joint Ventures
2% Total sales 2015 (pro-rata) : ~€1.9bn3
9% 7,000 18% Total EBITDA 2015 (pro-rata) : ~€245m3
17% 34% 32% 1,000
23%
5,000
31%
600
3,000
63% 69%
54% Other
37% Innovation Center & Other
200
1,000
Pharma
Polymer Intermediates
0 -1% 0
Performance Materials
2010 2015 2010 2015
Nutrition
1Other / Corporate Activities distributed over the Clusters pro-rata their EBITDA
2Restated, excluding Base Chemicals which was reported as Discontinued Operations
3 Includes DSM Sinochem Pharmaceuticals, DPx Patheon and ChemicaInvest (see page 40 for more detail)
Slide 4
Agenda

1 Strategy 2010-15
− Successful transformation
− Good growth platform created
•2 Strategy 2018
− Improve financial results, through
• Organic growth & business strategies
• Cost reduction & productivity improvements
• Capital efficiency
• Organization and culture
− Build for further future growth
− Extract value from Pharma & Bulk Chemicals
−3 Wrap-up
Slide 5